Edition:
United Kingdom

FDA Approves Paratek's Seysara For Treatment Of Moderate To Severe Acne


Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Paratek Pharmaceuticals Inc ::FDA APPROVES SEYSARA™ (SARECYCLINE) FOR THE TREATMENT OF MODERATE TO SEVERE ACNE.PARATEK PHARMACEUTICALS INC - PARATEK EARNS $12 MILLION MILESTONE PAYMENT.PARATEK PHARMA - EXCLUSIVELY LICENSED U.S. DEVELOPMENT & COMMERCIALIZATION RIGHTS OF SEYSARA TO ALLERGAN PLC, WHO HAS ASSIGNED SUCH RIGHTS TO ALMIRALL SA.PARATEK PHARMACEUTICALS - RETAINS DEVELOPMENT & COMMERCIALIZATION RIGHTS IN REST OF WORLD.PARATEK PHARMACEUTICALS - NOW ENTITLED TO RECEIVE TIERED ROYALTIES AT RATES RANGING FROM HIGH-SINGLE TO LOW DOUBLE DIGITS ON NET SALES OF SEYSARA. 

Company Quote

15.35
-0.28 -1.79%
13 Sep 2019